Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Activated charcoal for gut microbiome protection in lung cancer patients undergoing TEMLA
NCT04928950Phase 2Withdrawn
- Sponsor
- Masonic Cancer Center
- Start
- Jan 2022
- Primary completion
- Jan 2025
- Modality
- Small Molecules, Drug Delivery Systems
01
Overview
A Phase 2 trial of activated charcoal in dysbiosis, Clostridioides difficile infection (CDI), sponsored by Masonic Cancer Center. Planned start Jan 2022; status: withdrawn.
02
Drugs
activated charcoal
03
Conditions
dysbiosisClostridioides difficile infection (CDI)
Beyond the preview
Go deeper on NCT04928950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04928950.